Abstract
BACKGROUND—Bronchiolitis caused by respiratory syncytial virus (RSV) is an important cause of morbidity in ex-premature infants. In a randomised placebo controlled trial monoclonal antibody prophylaxis showed a 55% reduction in relative risk of hospital admission for these high risk infants, against a background incidence of 10.6 admissions per 100 high risk infants. AIMS—To follow a cohort of high risk infants in order to assess hospitalisation rate from RSV and the potential impact of prophylaxis for these patients in a UK local health authority. METHODS—A cohort of high risk infants from a local health authority were followed over the 1998/99 and 1999/2000 RSV seasons. The high risk population was defined as infants who, at the beginning of the seasons studied, were: (1) under 6 months old and born prior to 36 weeks gestation with no domiciliary oxygen requirement; or (2) under 24 months of age and discharged home in supplemental oxygen. All admissions with bronchiolitis during the season were identified. RESULTS—A total of 370 high risk infants were identified for the 1998/99 season and 286 for the following year. Over the two years there were 68 admissions. Significantly more admissions occurred from group 2 infants. RSV was identified in 27 cases (four admissions per hundred high risk infants). Prophylaxis may have saved up to £195 134 in hospital costs over the two years, but would have cost £1.1 million in drug acquisition costs. CONCLUSIONS—Careful consideration of risk factors is needed when selecting infants for RSV prophylaxis.
Full Text
The Full Text of this article is available as a PDF (108.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Groothuis J. R., Gutierrez K. M., Lauer B. A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988 Aug;82(2):199–203. [PubMed] [Google Scholar]
- Joffe S., Escobar G. J., Black S. B., Armstrong M. A., Lieu T. A. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999 Oct;104(4 Pt 1):894–899. doi: 10.1542/peds.104.4.894. [DOI] [PubMed] [Google Scholar]
- Joffe S., Ray G. T., Escobar G. J., Black S. B., Lieu T. A. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999 Sep;104(3 Pt 1):419–427. doi: 10.1542/peds.104.3.419. [DOI] [PubMed] [Google Scholar]
- Kristensen K., Dahm T., Frederiksen P. S., Ibsen J., Iyore E., Jensen A. M., Kjaer B. B., Olofsson K., Pedersen P., Poulsen S. Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. Pediatr Infect Dis J. 1998 Nov;17(11):996–1000. doi: 10.1097/00006454-199811000-00006. [DOI] [PubMed] [Google Scholar]
- Meert K., Heidemann S., Abella B., Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med. 1990 Dec;18(12):1357–1359. doi: 10.1097/00003246-199012000-00009. [DOI] [PubMed] [Google Scholar]
- Meert K., Heidemann S., Lieh-Lai M., Sarnaik A. P. Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host. Pediatr Pulmonol. 1989;7(3):167–170. doi: 10.1002/ppul.1950070309. [DOI] [PubMed] [Google Scholar]